<DOC>
	<DOCNO>NCT00126997</DOCNO>
	<brief_summary>This study assess immunogenicity safety GlaxoSmithKline ( GSK ) Biologicals live attenuate measles-mumps-rubella-varicella vaccine give healthy child second year life .</brief_summary>
	<brief_title>Immunogenicity Safety Combined Vaccine Prevent Measles , Mumps , Rubella Chickenpox Diseases</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female subject 1113 month age ( i.e . 11 month birthday day 14 month birthday ) time first vaccination . History previous measles , mumps , rubella and/or varicella vaccination disease , know exposure disease within 30 day prior start trial Planned administration vaccine foreseen study protocol 30 day prior vaccination 4256 day vaccination</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis measles , mumps , rubella chickenpox</keyword>
</DOC>